Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Safety and Efficacy of Inebilizumab in AQP4+ NMOSD Participants with History of Immunosuppression Treatment Prior to N-MOmentum Study

Author:Paul, Friedemann   Marignier, Roman   Lindsey, John   Kim, Ho Jin   She, Dewei   Cimbora, Daniel   Patterson, Kristina   Cree, Bruce   

Session Name:P13: Autoimmune Neurology: NMOSD / MOGAD / Optic Neuritis  

Topic:Autoimmune Neurology  

Program Number:P13.003  

Author Institution:Charite Universitatsmedizin in Berlin, Berlin, Germany  Hospices Civils de Lyon, Lyon, France  University of Texas Health Science Center at Houston, Houston, TX  National Cancer Center, Goyang, Korea, Republic of  Horizon Therapeutics plc, Gaithersburg, MD  Horizon Therapeutics plc, Deerfield, IL  UCSF, Multiple Sclerosis Center, San Francisco, CA  

Inebilizumab Reduces Attack Risk Independent of Low Affinity IgG Fc Region Receptor III-A Gene Polymorphisms in Neuromyelitis Optica Spectrum Disorder

Author:Weinshenker, Brian   Bennett, Jeffrey   Cree, Bruce   Paul, Friedemann   Kim, Ho Jin   Hartung, Hans-Peter   Patterson, Kristina   Smith, Michael   Rees, William   She, Dewei   Aktas, Orhan   

Session Name:P13: Autoimmune Neurology: NMOSD / MOGAD / Optic Neuritis  

Topic:Autoimmune Neurology  

Program Number:P13.015  

Author Institution:University of Virginia Health System, Charlottesville, VA  University of Colorado School of Medicine, Aurora, CO  UCSF, Multiple Sclerosis Center, San Francisco, CA  Charite Universitatsmedizin in Berlin, Berlin, Germany  National Cancer Center, Goyang, Korea, Republic of  Heinrich Heine University Medical Faculty Departme, Dusseldorf, Germany  Horizon Therapeutics plc, Deerfield, IL  Horizon Therapeutics plc, Gaithersburg, MD  Heinrich Heine University Düsseldorf, Düsseldorf, Germany